Is monitoring white blood cell counts necessary with lurbinectedin?
Yes, monitoring white blood cell (WBC) counts is necessary with lurbinectedin (brand name Zepzelca), a chemotherapy drug approved for metastatic small cell lung cancer. Neutropenia, a drop in neutrophils (a type of WBC), is the most common serious side effect, occurring in up to 65% of patients and leading to febrile neutropenia in 16%.[1][2]
Why does lurbinectedin cause low WBC counts?
Lurbinectedin inhibits DNA repair in rapidly dividing cancer cells but also affects bone marrow, suppressing neutrophil production. Severe neutropenia (grade 3-4) hits 51-57% of patients, with onset typically in the first or second cycle.[1][3]
How often should WBC counts be monitored?
Check complete blood counts (CBC), including differential WBC counts, before starting each cycle and as clinically indicated—often weekly during the first two cycles due to peak risk. Delay or reduce doses if absolute neutrophil count (ANC) falls below 1.5 × 10^9/L or platelets below 100 × 10^9/L.[1][2]
What happens if WBC counts drop too low?
Halt treatment until recovery to ANC ≥ 1.5 × 10^9/L and platelets ≥ 100 × 10^9/L. Use G-CSF (e.g., filgrastim) for prophylaxis or treatment in high-risk cases. Infections from neutropenia can be life-threatening; monitor for fever and symptoms.[1][3]
Are there dose adjustments based on monitoring?
Yes: Reduce from 3.2 mg/m² to 2.4 mg/m² (first reduction) or 1.6 mg/m² (second) for grade 4 neutropenia lasting over 7 days or with fever. Discontinue after two dose reductions or recurrent severe events.[2]
How does this compare to other chemotherapy drugs?
Lurbinectedin has higher neutropenia rates than topotecan (another SCLC drug, ~40% grade 3-4), but similar to platinum-etoposide combos. Routine G-CSF is more common here than with less myelosuppressive agents like immunotherapy.[3]
Sources
[1]: Zepzelca (lurbinectedin) prescribing information
[2]: FDA label summary
[3]: IMagine study (NCT02454972) results